Hims & Hers Health (HIMS) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.14
- Estimate
- $0.06
- Surprise
- -348.6%
- Revenue (period 2026-09-30)
- $890.4M
- Score today
- 5.5/10
Revenue source: xbrl.
How the report landed
Hims & Hers Health (HIMS) reported a wider loss than forecast — adjusted EPS of -$0.14 against the $0.06 estimate (a 348.6% shortfall).
Coverage in the report window
- These Analysts Revise Their Forecasts On Hims & Hers Health After Q3 Results — benzinga, 2026-11-10
- Evercore ISI Group Maintains In-Line on Hims & Hers Health, Raises Price Target to $27 — benzinga, 2026-11-10
- Hims & Hers Stock Feels a Pinch Tuesday: What's Happening? — benzinga, 2026-11-10
Where TrendMatrix's rating stands now
TrendMatrix currently rates HIMS Sell at 5.5/10; no pre/post engine snapshot brackets this report.
1 of the last 4 quarters beat the estimate; this quarter's -348.6% surprise compares with a -302.9% four-quarter average.
What argues against it
- Concentration risk — Geographic: United States
- Risk below floor (2.1 < 2.5)
- Momentum score 2.9/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $18.82
- Price target
- $27.10
- Stop
- $18.24
- Upside to target
- +44.0%
- Reward-to-risk
- 2.9:1
Risk check: RSI 26 — a level conventionally read as oversold; trading volume is running 2.5× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-11-10 — shown for context, not personalized investment advice.
HIMS at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - Specialty & Generic
- Market cap
- $5.35B
- P/E (fwd)
- 32.6
- 52-week range
- $13.74–$42.70
- Off 52-week high
- 55.9%
- RSI (14)
- 26
- Volume vs avg
- 2.47×
- Score today
- 5.5/10